英文摘要 |
Approximately 5% of all pregnancies are complicated by some form of diabetes, with gestational diabetes being the most prevalent. Diabetes in pregnancy will increase risks to the mother and the fetus. Women with gestational diabetes have an increased risk of developing diabetes later in life. Therefore, good glycemic control is very important for pregnant women. Primary therapy for gestational diabetes is life-style changes, including body weight control, diet control, exercise and self blood glucose monitoring. When life-style changes alone cannot control blood glucose, hypoglycemic drugs must be added. Several classes of hypoglycemic drugs are available, including insulin and oral hypoglycemic drugs. Insulin is not able to cross the placenta appreciably due to its high molecular weight. Therefore, insulin has been the drug of choice for diabetes during pregnancy. However, the invasive mode of insulin administration is not convenient for the user. In the past, oral hypoglycemic agents were contraindicated during pregnancy due to concerns of teratogenecity. Recently, some studies indicate that some oral hypoglycemic agents are safer than others for pregnant women and the fetus, such as glyburide, metformin and acarbose. Furthermore, a wide range of physiological changes occur during pregnancy. These changes can significantly affect pharmacokinetics of drugs. Therefore, when establishing a drug therapy plan for gestational diabetes, pharmacokinetic changes must be taken into consideration. This article reviews blood monitoring and therapy of gestational diabetes mellitus. For drug therapy, we emphasize that pharmacokinetic consideration of insulin or oral hypoglycemic agents should be incorporated into drug therapy choices. |